User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries

Primary tabs

Hermans, Michel [UCL] Brotons, Carlos Elisaf, Moses Michel, Georges Muls, Erik Nobels, Frank

Background: Micro- and macrovascular complications of type 2 diabetes have an adverse impact on survival, quality of life and healthcare costs. The OPTIMISE (OPtimal Type 2 dIabetes Management Including benchmarking and Standard trEatment) trial comparing physicians’ individual performances with a peer group evaluates the hypothesis that benchmarking, using assessments of change in three critical quality indicators of vascular risk: glycated haemoglobin (HbA1c), low-density lipoprotein-cholesterol (LDL-C) and systolic blood pressure (SBP), may improve quality of care in type 2 diabetes in the primary care setting. Design: This was a randomised, controlled study of 3980 patients with type 2 diabetes. Methods: Six European countries participated in the OPTIMISE study (NCT00681850). Quality of care was assessed by the percentage of patients achieving pre-set targets for the three critical quality indicators over 12 months. Physicians were randomly assigned to receive either benchmarked or non-benchmarked feedback. All physicians received feedback on six of their patients’ modifiable outcome indicators (HbA1c, fasting glycaemia, total cholesterol, high-density lipoprotein-cholesterol (HDL-C), LDL-C and triglycerides). Physicians in the benchmarking group additionally received information on levels of control achieved for the three critical quality indicators compared with colleagues. Results: At baseline, the percentage of evaluable patients (N = 3980) achieving pre-set targets was 51.2% (HbA1c; n = 2028/3964); 34.9% (LDL-C; n = 1350/3865); 27.3% (systolic blood pressure; n = 911/3337). Conclusions: OPTIMISE confirms that target achievement in the primary care setting is suboptimal for all three critical quality indicators. This represents an unmet but modifiable need to revisit the mechanisms and management of improving care in type 2 diabetes. OPTIMISE will help to assess whether benchmarking is a useful clinical tool for improving outcomes in type 2 diabetes.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2013
Language Anglais
Journal information "European journal of preventive cardiology" - Vol. 20, no. 6, p. 1095-1105 (2013)
Peer reviewed yes
Publisher Sage Publications Ltd. ((United Kingdom) London)
issn 2047-4873
e-issn 2047-4881
Publication status Publié
Affiliations UCL - SSS/IREC/EDIN - Pôle d'endocrinologie, diabète et nutrition
UCL - (SLuc) Service d'endocrinologie et de nutrition
Links
  1. Kannel William B., Wilson Peter W.F., Zhang Ting-Jie, The epidemiology of impaired glucose tolerance and hypertension, 10.1016/0002-8703(91)90432-h
  2. Oldridge Neil B., Stump Timothy E., Nothwehr Faryle K., Clark Daniel O., Prevalence and outcomes of comorbid metabolic and cardiovascular conditions in middle- and older-age adults, 10.1016/s0895-4356(01)00350-x
  3. Haffner S. M., Management of Dyslipidemia in Adults With Diabetes, 10.2337/diacare.21.1.160
  4. Lipton Rebecca B., Uao Youlian, Cao Guichan, Cooper Richard S., McGee Daniel, Determinants of Incident Non-lnsulin-dependent Diabetes Mellitus among Blacks and Whites in a National Sample, 10.1093/oxfordjournals.aje.a116786
  5. Alexander C. M., Landsman P. B., Teutsch S. M., Haffner S. M., NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older, 10.2337/diabetes.52.5.1210
  6. Juutilainen A., Lehto S., Ronnemaa T., Pyorala K., Laakso M., Type 2 Diabetes as a "Coronary Heart Disease Equivalent": An 18-year prospective population-based study in Finnish subjects, 10.2337/diacare.28.12.2901
  7. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), 10.1016/s0140-6736(98)07019-6
  8. UK Prospective Diabetes Study Group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38, 10.1136/bmj.317.7160.703
  9. Effects of Different Blood Pressure–Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus : Results of Prospectively Designed Overviews of Randomized Trials, 10.1001/archinte.165.12.1410
  10. Pyorala K., Pedersen T. R., Kjekshus J., Faergeman O., Olsson A. G., Thorgeirsson G., , Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), 10.2337/diacare.20.4.614
  11. Goldberg R. B., Mellies M. J., Sacks F. M., Moye L. A., Howard B. V., Howard W. J., Davis B. R., Cole T. G., Pfeffer M. A., Braunwald E., Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels : Subgroup Analyses in the Cholesterol And Recurrent Events (CARE) Trial, 10.1161/01.cir.98.23.2513
  12. Haffner Steven M., Reduced Coronary Events in Simvastatin-Treated Patients With Coronary Heart Disease and Diabetes or Impaired Fasting Glucose Levels : Subgroup Analyses in the Scandinavian Simvastatin Survival Study, 10.1001/archinte.159.22.2661
  13. Selvin Elizabeth, Marinopoulos Spyridon, Berkenblit Gail, Rami Tejal, Brancati Frederick L., Powe Neil R., Golden Sherita Hill, Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus, 10.7326/0003-4819-141-6-200409210-00007
  14. Stratton I. M, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, 10.1136/bmj.321.7258.405
  15. Gerstein H. C., Pogue J., Mann J. F. E., Lonn E., Dagenais G. R., McQueen M., Yusuf S., , The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis, 10.1007/s00125-005-1858-4
  16. Effects of Intensive Glucose Lowering in Type 2 Diabetes, 10.1056/nejmoa0802743
  17. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes, 10.1056/nejmoa0802987
  18. Duckworth William, Abraira Carlos, Moritz Thomas, Reda Domenic, Emanuele Nicholas, Reaven Peter D., Zieve Franklin J., Marks Jennifer, Davis Stephen N., Hayward Rodney, Warren Stuart R., Goldman Steven, McCarren Madeline, Vitek Mary Ellen, Henderson William G., Huang Grant D., Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes, 10.1056/nejmoa0808431
  19. Ray Kausik K, Seshasai Sreenivasa Rao Kondapally, Wijesuriya Shanelle, Sivakumaran Rupa, Nethercott Sarah, Preiss David, Erqou Sebhat, Sattar Naveed, Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials, 10.1016/s0140-6736(09)60697-8
  20. Hansson Lennart, Zanchetti Alberto, Carruthers S George, Dahlöf Björn, Elmfeldt Dag, Julius Stevo, Ménard Joël, Rahn Karl Heinz, Wedel Hans, Westerling Sten, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial, 10.1016/s0140-6736(98)04311-6
  21. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), 10.1001/jama.288.23.2981
  22. Patel Anushka, Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial, 10.1016/s0140-6736(07)61303-8
  23. Adler A. I, Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study, 10.1136/bmj.321.7258.412
  24. , Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis, 10.1016/s0140-6736(08)60104-x
  25. Gæde Peter, Lund-Andersen Henrik, Parving Hans-Henrik, Pedersen Oluf, Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes, 10.1056/nejmoa0706245
  26. Hermans Michel P, Non-invited Review: Prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD, 10.1177/1479164111407783
  27. Andel M., Grzeszczak W., Michalek J., Medvescek M., Norkus A., Rasa I., Niewada M., Kamiński B., Kraml P., Madacsy L., , A multinational, multi-centre, observational, cross-sectional survey assessing diabetes secondary care in Central and Eastern Europe (DEPAC Survey), 10.1111/j.1464-5491.2008.02570.x
  28. Huppertz E., Pieper L., Klotsche J., Stridde E., Pittrow D., Böhler S., Lehnert H., Diabetes Mellitus in German Primary Care: Quality of Glycaemic Control and Subpopulations not well Controlled – Results of the DETECT Study, 10.1055/s-2008-1073127
  29. Nobels F, Rev Med Liege, 60, 624 (2005)
  30. Debacker N., Nobels F., Vandenberghe H., Van Crombrugge P., Scheen A., Van Casteren V., Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years’ experience, 10.1111/j.1464-5491.2007.02378.x
  31. Bodenheimer Thomas, Improving Primary Care for Patients With Chronic Illness, 10.1001/jama.288.14.1775
  32. Bodenheimer Thomas, Wagner Edward H., Grumbach Kevin, Improving Primary Care for Patients With Chronic Illness : The Chronic Care Model, Part 2, 10.1001/jama.288.15.1909
  33. Bodenheimer Thomas, Patient Self-management of Chronic Disease in Primary Care, 10.1001/jama.288.19.2469
  34. Plsek PE, Pediatrics, 103, E203 (1999)
  35. Kiefe Catarina I., Allison Jeroan J., Williams O. Dale, Person Sharina D., Weaver Michael T., Weissman Norman W., Improving Quality Improvement Using Achievable Benchmarks For Physician Feedback : A Randomized Controlled Trial, 10.1001/jama.285.22.2871
  36. Smith Steven A., Shah Nilay D., Bryant Sandra C., Christianson Teresa J.H., Bjornsen Susan S., Giesler Paula D., Krause Kathleen, Erwin Patricia J., Montori Victor M., Chronic Care Model and Shared Care in Diabetes: Randomized Trial of an Electronic Decision Support System, 10.4065/83.7.747
  37. Nobels Frank, Debacker Noëmi, Brotons Carlos, Elisaf Moses, Hermans Michel P, Michel Georges, Muls Erik, , Study rationale and design of OPTIMISE, a randomised controlled trial on the effect of benchmarking on quality of care in type 2 diabetes mellitus, 10.1186/1475-2840-10-82
  38. Ryden L., Standl E., Rimonabant as an adjunct therapy in overweight/obese patients with type 2 diabetes: reply, 10.1093/eurheartj/ehm124
  39. , Generic Drugs, 10.2337/dc07-9918
  40. Mancia Giuseppe, De Backer Guy, Dominiczak Anna, Cifkova Renata, Fagard Robert, Germano Giuseppe, Grassi Guido, Heagerty Anthony M, Kjeldsen Sverre E, Laurent Stephane, Narkiewicz Krzysztof, Ruilope Luis, Rynkiewicz Andrzej, Schmieder Roland E, Boudier Harry AJ Struijker, Zanchetti Alberto, 2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 10.1097/hjh.0b013e3281fc975a
  41. Eccles Martin P, Whitty Paula M, Speed Chris, Steen Ian N, Vanoli Alessandra, Hawthorne Gillian C, Grimshaw Jeremy M, Wood Linda J, McDowell David, A pragmatic cluster randomised controlled trial of a Diabetes REcall And Management system: the DREAM trial, 10.1186/1748-5908-2-6
  42. Lachin JM, Biostatistical methods (2002)
  43. Machin D, Sample size tables or clinical studies (1997)
  44. Stamler J., Vaccaro O., Neaton J. D., Wentworth D., , Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial, 10.2337/diacare.16.2.434
  45. Harris MI, Diabetes in America (1995)
  46. Caro J. J., Ward A. J., O'Brien J. A., Lifetime Costs of Complications Resulting From Type 2 Diabetes in the U.S., 10.2337/diacare.25.3.476
  47. Serrano-Gil Manuel, Jacob Stephan, Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?, 10.1007/s12325-010-0034-5
  48. Spann S. J., Management of Type 2 Diabetes in the Primary Care Setting: A Practice-Based Research Network Study, 10.1370/afm.420
  49. Andros V, J Manag Care Pharm, 12, 303 (2006)
  50. Hermans Michel P., Amoussou-Guenou K. Daniel, Ahn Sylvie A., Rousseau Michel F., Everaert Ludwig, Aerts Ann, The elusive type 2 diabetes individual achieving tight blood pressure target: A phenotypic study, 10.1016/j.dsx.2010.07.012
  51. Hermans Michel P., Castro Cabezas Manuel, Strandberg Timo, Ferrières Jean, Feely John, Elisaf Moses, Michel Georges, Sansoy Vedat, Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries, 10.1185/03007990903500565
  52. Bailie Ross, Si Damin, Connors Christine, Weeramanthri Tarun, Clark Louise, Dowden Michelle, O'Donohue Lynette, Condon John, Thompson Sandra, Clelland Nikki, Nagel Tricia, Gardner Karen, Brown Alex, Study protocol: Audit and Best Practice for Chronic Disease Extension (ABCDE) Project, 10.1186/1472-6963-8-184
  53. Hermans MP, Recent advances in the pathogenesis, prevention and management of type 2 diabetes and its complications, 45 (2011)
  54. Redon Josep, Brunner Hans R, Ferri Claudio, Hilgers Karl F, Kolloch Rainer, van Montfrans Gert, Practical solutions to the challenges of uncontrolled hypertension: a white paper : , 10.1097/01.hjh.0000343507.74401.45
  55. Robin DiMatteo M., Giordani Patrick J., Lepper Heidi S., Croghan Thomas W., Patient Adherence and Medical Treatment Outcomes : A Meta-Analysis, 10.1097/00005650-200209000-00009
  56. Krousel-Wood Marie, Thomas Sheila, Muntner Paul, Morisky Donald, Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients : , 10.1097/01.hco.0000126978.03828.9e
  57. Owen AJ, Retegan C, Rockell M, Jennings G, Reid CM, INERTIA OR INACTION? BLOOD PRESSURE MANAGEMENT AND CARDIOVASCULAR RISK IN DIABETES, 10.1111/j.1440-1681.2008.05125.x
  58. Brunzell J. D., Davidson M., Furberg C. D., Goldberg R. B., Howard B. V., Stein J. H., Witztum J. L., Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, 10.2337/dc08-9018
Bibliographic reference Hermans, Michel ; Brotons, Carlos ; Elisaf, Moses ; Michel, Georges ; Muls, Erik ; et. al. Optimal type 2 diabetes mellitus management: the randomised controlled OPTIMISE benchmarking study: baseline results from six European countries. In: European journal of preventive cardiology, Vol. 20, no. 6, p. 1095-1105 (2013)
Permanent URL http://hdl.handle.net/2078.1/132409